Apogee Therapeutics Common Stock Performance
| APGE Stock | 62.24 0.11 0.18% |
On a scale of 0 to 100, Apogee Therapeutics holds a performance score of 4. The firm shows a Beta (market volatility) of 1.21, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Apogee Therapeutics will likely underperform. Please check Apogee Therapeutics' total risk alpha, downside variance, daily balance of power, as well as the relationship between the maximum drawdown and skewness , to make a quick decision on whether Apogee Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Soft
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Apogee Therapeutics Common are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of rather unfluctuating technical and fundamental indicators, Apogee Therapeutics exhibited solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 0.18 | Five Day Return (1.38) | Year To Date Return (17.87) | Ten Year Return 193.17 | All Time Return 193.17 |
1 | Disposition of 2000 shares by Jane Henderson of Apogee Therapeutics, at 65.0 subject to Rule 16b-3 | 11/14/2025 |
2 | Disposition of 1500 shares by Jane Henderson of Apogee Therapeutics, at 70.0 subject to Rule 16b-3 | 11/25/2025 |
3 | Disposition of 40000 shares by Henderson Michael Thomas of Apogee Therapeutics, at 75.01 subject to Rule 16b-3 | 12/04/2025 |
4 | Strong Pipeline and Analyst Confidence Push Apogee Therapeutics Inc. Toward Growth | 12/09/2025 |
5 | Apogee Therapeutics Shares Gap Down Heres Why | 01/06/2026 |
6 | Disposition of 14025 shares by Dambkowski Carl of Apogee Therapeutics at 22.86 subject to Rule 16b-3 | 01/07/2026 |
7 | Apogee Therapeutics Price Target Raised to 128.00 | 01/08/2026 |
8 | How Investors Are Reacting To Apogee Therapeutics Asthma Data and 2026 Immunology Pipeline Ambitions | 01/15/2026 |
9 | Disposition of 1750000 shares by Fairmount Funds Management Llc of Apogee Therapeutics at 76.3 subject to Rule 16b-3 | 01/22/2026 |
10 | Disposition of 100 shares by Jane Henderson of Apogee Therapeutics at 66.89 subject to Rule 16b-3 | 02/02/2026 |
11 | Disposition of 7365 shares by Dambkowski Carl of Apogee Therapeutics at 22.86 subject to Rule 16b-3 | 02/03/2026 |
12 | Disposition of 4125 shares by Dambkowski Carl of Apogee Therapeutics at 22.86 subject to Rule 16b-3 | 02/04/2026 |
13 | Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook Biotech Summit 2026 | 02/05/2026 |
| Begin Period Cash Flow | 118.6 M | |
| Total Cashflows From Investing Activities | -300.5 M |
Apogee Therapeutics Relative Risk vs. Return Landscape
If you would invest 5,677 in Apogee Therapeutics Common on November 10, 2025 and sell it today you would earn a total of 547.00 from holding Apogee Therapeutics Common or generate 9.64% return on investment over 90 days. Apogee Therapeutics Common is currently generating 0.2001% in daily expected returns and assumes 3.2258% risk (volatility on return distribution) over the 90 days horizon. In different words, 28% of stocks are less volatile than Apogee, and 96% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Apogee Therapeutics Target Price Odds to finish over Current Price
The tendency of Apogee Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 62.24 | 90 days | 62.24 | about 88.02 |
Based on a normal probability distribution, the odds of Apogee Therapeutics to move above the current price in 90 days from now is about 88.02 (This Apogee Therapeutics Common probability density function shows the probability of Apogee Stock to fall within a particular range of prices over 90 days) .
Apogee Therapeutics Price Density |
| Price |
Predictive Modules for Apogee Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Apogee Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Apogee Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Apogee Therapeutics is not an exception. The market had few large corrections towards the Apogee Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Apogee Therapeutics Common, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Apogee Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.15 | |
β | Beta against Dow Jones | 1.21 | |
σ | Overall volatility | 7.73 | |
Ir | Information ratio | 0.05 |
Apogee Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Apogee Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Apogee Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Apogee Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (182.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Apogee Therapeutics generates negative cash flow from operations | |
| Apogee Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook Biotech Summit 2026 |
Apogee Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Apogee Stock often depends not only on the future outlook of the current and potential Apogee Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Apogee Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 55.2 M | |
| Cash And Short Term Investments | 520.7 M |
Apogee Therapeutics Fundamentals Growth
Apogee Stock prices reflect investors' perceptions of the future prospects and financial health of Apogee Therapeutics, and Apogee Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apogee Stock performance.
| Return On Equity | -0.38 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 3.73 B | ||||
| Shares Outstanding | 54.83 M | ||||
| Price To Book | 7.25 X | ||||
| EBITDA | (216.68 M) | ||||
| Net Income | (182.15 M) | ||||
| Total Debt | 11.83 M | ||||
| Book Value Per Share | 9.88 X | ||||
| Cash Flow From Operations | (171.17 M) | ||||
| Earnings Per Share | (4.38) X | ||||
| Market Capitalization | 4.25 B | ||||
| Total Asset | 753.95 M | ||||
| Retained Earnings | (305.92 M) | ||||
| Working Capital | 501.15 M | ||||
About Apogee Therapeutics Performance
By analyzing Apogee Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Apogee Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Apogee Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Apogee Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.22) | (0.23) | |
| Return On Capital Employed | (0.34) | (0.36) | |
| Return On Assets | (0.22) | (0.23) | |
| Return On Equity | (0.23) | (0.24) |
Things to note about Apogee Therapeutics performance evaluation
Checking the ongoing alerts about Apogee Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apogee Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Apogee Therapeutics had very high historical volatility over the last 90 days | |
| Net Loss for the year was (182.15 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Apogee Therapeutics generates negative cash flow from operations | |
| Apogee Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from globenewswire.com: Apogee Therapeutics to Participate at the Guggenheim Emerging Outlook Biotech Summit 2026 |
- Analyzing Apogee Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apogee Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Apogee Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Apogee Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apogee Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Apogee Therapeutics' stock. These opinions can provide insight into Apogee Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Apogee Stock analysis
When running Apogee Therapeutics' price analysis, check to measure Apogee Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Apogee Therapeutics is operating at the current time. Most of Apogee Therapeutics' value examination focuses on studying past and present price action to predict the probability of Apogee Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Apogee Therapeutics' price. Additionally, you may evaluate how the addition of Apogee Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |